Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 13 2021 - 9:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of January 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£ 13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr R Connor
|
|
b)
|
Position/status
|
President,
Global Vaccines
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms D Conrad
|
|
b)
|
Position/status
|
SVP,
Human Resources
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr J Ford
|
|
b)
|
Position/status
|
SVP and
General Counsel
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP,
Global Ethics and Compliance
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms S Jackson
|
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr D Jackson
|
|
b)
|
Position/status
|
PCA of
Ms S Jackson (SVP, Global Communications and CEO
Office)
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr D Redfern
|
|
b)
|
Position/status
|
Chief
Strategy Officer
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr R Simard
|
|
b)
|
Position/status
|
President,
Pharmaceuticals Supply Chain
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr P Thomson
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms D Waterhouse
|
|
b)
|
Position/status
|
Chief
Executive Officer of ViiV Healthcare
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms V Whyte
|
|
b)
|
Position/status
|
Company
Secretary
|
|
c)
|
Initial notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8425
|
9 (partnership shares)
|
|
|
|
£13.8425
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£13.8425
|
|
e)
|
Date of the transaction
|
2021-01-12
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: January
13, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
